Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312707 | 0.89 | POLB (1.00) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2853774 | 0.88 | POLB (0.83) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL12445438 | 0.87 | POLB (0.83) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL18778790 | 0.86 | POLB (0.81) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL11518673 | 0.86 | MEN1 (0.63) | POLBALDH1A1KMT2AMEN1LMNA | |
| Fenacetinol SCHEMBL2850567 | 0.86 | POLB (0.80) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5808300 | 0.84 | POLB (0.77) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL9842944 | 0.84 | POLB (0.77) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5808296 | 0.84 | POLB (0.77) | POLBALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL29270204 | 0.84 | POLB (0.77) | POLBALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206500-A | Extraction method of phenamine mycin | 上海农乐生物制品股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117729917-A | Combination therapy using AKR1C3 activating compounds and immune checkpoint inhibitors | 深圳艾欣达伟医药科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-113249007-B | Primer composition and method of coating a substrate | 艾仕得涂料系统有限责任公司 | 2024-03-15 | — | — | CN | claimed |
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | OCULAR THERAPEUTIX INC (US) | 2023-09-14 | — | — | US | claimed |
| EP-4236943-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | Ocular Therapeutix, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116459402-A | Nanofiber with unidirectional drainage capability, preparation method and application thereof | 四川大学 | 2023-07-21 | — | — | CN | claimed |
| CN-113713169-B | Near-infrared light-sensitive ZIF8 functionalized gelatin nanofiber scaffold system and application thereof | 温州医科大学 | 2023-07-11 | — | — | CN | claimed |
| CN-116209475-A | Therapeutic uses comprising a triple agonist long-acting conjugate or a combination of triple agonists | 韩美药品株式会社 | 2023-06-02 | — | — | CN | claimed |
| CN-113880779-B | Extraction method of phenamine mycin | 上海农乐生物制品股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115709158-A | Metal long-acting anticorrosion phenolic amine modified sol-gel film and preparation method thereof | 中山大学 | 2023-02-24 | — | — | CN | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| EP-1169298-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-1191553-A | Method for examining lung disease | UNIV NORTH CAROLINA CHAPEL HILL (US) | 1998-08-26 | — | — | CN | claimed |
| CN-1189097-A | Dinucleotides for the treatment of pulmonary diseases | UNIV NORTH CAROLINA CHAPEL HILL (US) | 1998-07-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | ERBB2, BTK, ERBB3 | POLB 4423/4885ALDH1A1 1122/4885KMT2A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.